Clinical Trial

Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-22.
Trial Details
NCT Number NCT07615101
Lead Sponsor Norroy Bioscience Co., LTD
Conditions Prostate Cancer (Diagnosis)
Enrollment 365 participants
Start Date 2026-06-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-01